IGI Laboratories president and CEO Jason Grenfell-Gardner said: "We believe our current pipeline of twenty-nine submissions, exclusive of our four partnered submissions, pending approval by the FDA now has a combined addressable market of over $1.4 billion based on July 2015 data from IMS Health."